Nantahala Capital Management, LLC
Position in GRCE — Grace Therapeutics, Inc.
CIK 1472322
New Canaan, CT
Position in GRCE
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$3,371,579
-$705,003 QoQ
Shares Held
728,203
-38.2% QoQ
Ownership
3.46%
of shares outstanding
% of Portfolio
0.22%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GRCE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Nantahala Capital Management, LLC holds $620,287,047 across 52 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SVRA |
Savara Inc
|
6,976,810 | $42,977,149 | |
| 2 | AVTX |
Avalo Therapeutics, Inc.
|
1,862,250 | $34,414,380 | |
| 3 | LBRX |
Lb Pharmaceuticals Inc
|
1,052,894 | $34,171,674 | |
| 4 | ABEO |
Abeona Therapeutics Inc.
|
5,136,490 | $31,743,508 | |
| 5 | ZVRA |
Zevra Therapeutics, Inc.
|
1,797,476 | $25,775,805 | |
| 6 | MLYS |
Mineralys Therapeutics, Inc.
|
820,481 | $22,136,577 | |
| 7 | QURE |
uniQure N.V.
|
455,660 | $20,987,699 | |
| 8 | AURA |
Aura Biosciences, Inc.
|
2,951,030 | $20,952,313 |
All Filings in GRCE
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,674,520 | 1,178,203 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $3,371,579 | 728,203 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $4,076,582 | 1,178,203 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $3,511,044 | 1,178,203 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $3,499,262 | 1,178,203 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $2,686,302 | 1,178,203 | Shares | Sole | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||